{"disease":{"id":"mild-cognitive-impairment-due-to-alzheimer-s-disease","name":"mild cognitive impairment due to alzheimer s disease"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT06058234","title":"Medicare Anti-Aβ mAb Coverage With Evidence Development (CED) Study","phase":"","overall_status":"RECRUITING","enrollment_count":8680,"lead_sponsor_name":"Centers for Medicare and Medicaid Services/ Coverage and Analysis Group","has_results":false},{"nct_id":"NCT01931566","title":"Biomarker Qualification for Risk of Mild Cognitive Impairment (MCI) Due to Alzheimer's Disease (AD) and Safety and Efficacy Evaluation of Pioglitazone in Delaying Its Onset","phase":"PHASE3","overall_status":"TERMINATED","enrollment_count":3494,"lead_sponsor_name":"Takeda","has_results":true},{"nct_id":"NCT05399888","title":"A Study to Learn About the Safety of BIIB080 Injections and Whether They Can Improve Symptoms of Participants With Mild Cognitive Impairment Due to Alzheimer's Disease (AD) or Mild AD Dementia Between 50 to 80 Years of Age","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":416,"lead_sponsor_name":"Biogen","has_results":false},{"nct_id":"NCT06182085","title":"Study to Assess Safety and Efficacy of PRI-002 in Patients With MCI to Mild Dementia Due to Alzheimer's Disease (AD)","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":304,"lead_sponsor_name":"PRInnovation GmbH","has_results":false},{"nct_id":"NCT05542953","title":"[18F]APN-1607 PET in Subjects With AD Compared to HC","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":230,"lead_sponsor_name":"APRINOIA Therapeutics","has_results":false},{"nct_id":"NCT06792877","title":"Mindfulness for Cognition in Early-stage Alzheimer's Disease","phase":"NA","overall_status":"RECRUITING","enrollment_count":100,"lead_sponsor_name":"VA Boston Healthcare System","has_results":false},{"nct_id":"NCT06618807","title":"Infrared Light for Memory Loss in Mild Cognitive Impairment (MCI)","phase":"NA","overall_status":"RECRUITING","enrollment_count":60,"lead_sponsor_name":"Unity Health Toronto","has_results":false},{"nct_id":"NCT05582941","title":"Biomarkers of Cognitive Impairment in Blood Cells","phase":"","overall_status":"COMPLETED","enrollment_count":48,"lead_sponsor_name":"University of the Balearic Islands","has_results":false},{"nct_id":"NCT02284906","title":"AD-4833/TOMM40_303 Extension Study of the Safety and Efficacy of Pioglitazone to Slow Cognitive Decline in Participants With Mild Cognitive Impairment Due to Alzheimer Disease","phase":"PHASE3","overall_status":"TERMINATED","enrollment_count":40,"lead_sponsor_name":"Takeda","has_results":true},{"nct_id":"NCT04711486","title":"Evaluation of Safety of Contraloid Acetate in Patients With Mild Cognitive Impairment Due to Alzheimer's Disease","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":19,"lead_sponsor_name":"Charite University, Berlin, Germany","has_results":false}],"total":10},"guidelines":[],"source":"Drug Landscape verified database"}